Galectin Therapeutics
GALT
55 hedge funds and large institutions have $53.9M invested in Galectin Therapeutics in 2014 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 15 increasing their positions, 5 reducing their positions, and 4 closing their positions.
550% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 4
328% more capital invested
Capital invested by funds: $12.6M → $53.9M (+$41.3M)
200% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 5
67% more funds holding
Funds holding: 33 → 55 (+22)
61% less call options, than puts
Call options by funds: $3.35M | Put options by funds: $8.65M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$5.69M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$4.96M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.91M |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$2.85M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$2.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$1.65M |
| 2 |
Neuberger Berman Group
New York
|
-$673K |
| 3 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
-$602K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$447K |
| 5 |
LOM
Loeb Offshore Management
New York
|
-$90K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$171 | -12 | -11% |
|
|
PSI
52
Pinnacle Summer Investments
Fairfax,
Virginia
| $2K | – | – | – |
|
53
Barclays
London,
United Kingdom
| $1K | -$46K | -3,231 | -98% |
|
54
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $2 | – | – | – |
|
|
CCA
55
Catalyst Capital Advisors
Huntington,
New York
| – | -$1.65M | -204,000 | Closed |
|
|
WAM
56
Wolverine Asset Management
Chicago,
Illinois
| – | -$447K | -55,439 | Closed |
|
|
LOM
57
Loeb Offshore Management
New York
| – | -$90K | -11,179 | Closed |
|
|
MWP
58
MYCIO Wealth Partners
Philadelphia,
Pennsylvania
| – | -$16K | -2,000 | Closed |
|
59
BlackRock
New York
| – | +$43 | +3 | New |
|
GALT Hedge Fund Activity: Q1 2014 in Review
55 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q1 2014, worth a combined $53.9M — up 328% from $12.6M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new GALT positions and 4 closed out — a net gain of 22 holders — while 15 added to existing stakes and 5 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $5.69M. The largest seller was Catalyst Capital Advisors, exiting entirely with an estimated $1.65M sold.
- 55 institutional investors held Galectin Therapeutics (GALT) as of Q1 2014, up from 33 in Q4 2013.
- Funds reported $53.9M of Galectin Therapeutics stock for Q1 2014, up 328% quarter-over-quarter.
- 26 funds opened new Galectin Therapeutics positions in Q1 2014 and 4 closed out, a net change of +22 holders.
- The largest Galectin Therapeutics buyer in Q1 2014 was Baker Bros. Advisors, an estimated $5.69M added.
- The largest Galectin Therapeutics seller in Q1 2014 was Catalyst Capital Advisors, an estimated $1.65M sold.
Based on aggregated 13F filings for Q1 2014.